Original Article

Details of recurrence sites after definitive radiation therapy for cervical cancer

Reiko Kobayashi, Hideomi Yamashita*, Kae Okuma, Kuni Ohtomo, Keiichi Nakagawa
Department of Radiology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.

*Corresponding author: Hideomi Yamashita, M.D. Ph. D.
Department of Radiology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan.
7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655 Japan.
Tel: (+81) 3-5800-8667;
Fax: (+81) 3-5800-8935;
E-mail: yamachan07291973@yahoo.co.jp

Running head: Recurrence sites after RT for cervical cancer

Received 3 Jun, 2015  Revised 9 Sep, 2015  Accepted 15 Sep, 2015
Abstract

Objective: This is a retrospective study aimed at clarifying the details of recurrence patterns and sites in patients with cervical cancer treated with definitive radiation therapy (RT).

Methods: Data were analyzed from consecutive patients, admitted to our institution between 2001 and 2013, who had received definitive RT, with or without chemotherapy, for International Federation of Gynecology and Obstetrics stages IB–IVA cervical cancer.

Results: One hundred and thirty-seven patients formed the patient cohort. The median follow-up period for surviving patients was 57.0 months. A complete response was achieved in 121 (88%) patients. Of these, 36 (30%) developed a cancer recurrence during follow-up. The first sites of recurrence were located in intra-RT fields in nine, outside RT fields in 20, and both in seven patients. In the intra-RT field group, all patients showed a local recurrence, while no one experienced an isolated pelvic lymph node (PLN) recurrence. In the outside RT field group, the most frequent site of recurrence was lung (60%), and three-quarters of patients were free from intra-RT field recurrence until the last follow-up. Of the entire cohort, including 48 PLN-positive patients, only seven (5.1%) patients developed PLN persistence or recurrence, all in the common iliac, internal iliac, and/or obturator nodes, and all with another synchronous relapse.

Conclusion: Local disease was a major type of intra-RT field recurrence, while PLN control was favorable even in initially PLN-positive patients. The predominance of outside RT field recurrence alone highlights issues concerning distant control, including the intensity enhancement of systematic therapy.

Keywords: Uterine Cervical Neoplasms; Radiation Therapy; Recurrence; Relapse
Introduction

Definitive radiation therapy (RT) for cervical cancer has changed dramatically over the last few decades in terms of two major advances, the combination use of chemotherapy and RT technological advances. Concomitant chemoradiation therapy (CRT) has become widely accepted as the standard care for locally advanced cervical cancer according to the Clinical Announcement by the US National Cancer Institute in 1999 [1, 2]. Chemotherapy serves as a radiosensitizer that enhances the activity of radiation, and as a direct cytotoxin to local tumor cells and subclinical distant metastases beyond the radiation field [3]. A recent meta-analysis of 13 randomized controlled trials (RCTs) comparing CRT versus RT found a 6% improvement in 5-year survival in favor of CRT, with a hazard ratio of 0.81 ($P < 0.001$) [4, 5]. CRT also reduced local and distant cervical cancer recurrence and progression, and improved disease-free survival, in particular, in International Federation of Gynecology and Obstetrics (FIGO) stages I–II disease [4]. At the same time, extensive RT technological advances have been made, especially in the field of brachytherapy. Image-guided brachytherapy (IGBT) has allowed the delineation of clinical target volumes (CTVs) and organs at risk (OARs), resulting in a dose prescription for these volumes. IGBT has also allowed for adaptive brachytherapy to the tumor at the time of treatment, taking tumor regression into account [6]. Thus, IGBT have provided improvements in dose distribution and dose escalation to the target, leading to high local control rates, even in advanced stages of cervical cancer [7].

However, locoregional and distant failures were still encountered. Once recurrence occurs, further treatment options are severely limited and the outcome is usually dismal. Up until now, recurrence patterns have been shown in only a few studies [6, 8]; it seems that distant metastases became the first site of recurrence, caused by increased locoregional control rates [6, 9]. Mazeron et al. reported that among 163 patients, with a median follow-up of 36 months, who were treated with CRT for FIGO stages IB–IVA diseases, those who developed distant metastasis as the first relapse accounted for 68.7% of all relapses, and, of these, half were isolated [6]; however, details remain to be investigated. The purpose of this retrospective study was to clarify the details of recurrence patterns.
and sites in a large cohort of cervical cancer patients treated with modern definitive RT at a single institution.
Materials and Methods

Patient population

Between 2001 and 2013, data was obtained on consecutive patients who met the following eligibility requirements: a diagnosis of pathologically confirmed cervical cancer, FIGO clinical stages IB to IVA disease, and received definitive RT consisting of external beam RT (EBRT) and high-dose rate intra-cavitary or interstitial brachytherapy (HDR-ICBT and HDR-ISBT, respectively) at our institution. Patients with para-aortic lymph node (PALN) metastasis were included. Patients were excluded if they: did not complete the planned RT, received any prior treatment for cervical cancer except conization, had other simultaneous uncontrollable malignancies, and/or were not followed at our institution.

This research was reviewed and approved by the Institutional Review Board of the University of Tokyo Hospital. All patient identifiers were removed prior to the analysis of data.

Pretreatment evaluation

All patients were clinically evaluated for their pretreatment state by a physical and pelvic examination without anesthesia, a biopsy of the primary tumor, a complete blood cell count and biochemistry profile, a computed tomography (CT) of chest, abdomen and pelvis, and by magnetic resonance imaging (MRI) of the pelvis. Drip infusion pyelography, cystoscopy, and rectoscopy were performed when possible. Prior to 2008, [18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) was performed when possible, and from 2008, it was routinely performed. Pelvic lymph nodes (PLNs) greater than or equal to 10 mm minimum in diameter on CT or MRI, smaller but considered to be metastases by specialists in diagnostic radiology, or positive by FDG-PET (diagnosed by specialists in nuclear medicine) were assessed as positive. All patients were assigned to a clinical stage on the basis of their FIGO classification.
Treatment schedule

RT consisted of EBRT to the whole pelvis as well as HDR-ICBT.

EBRT was administered with 6 or 10 MV photon-beams to the whole pelvis using a four-field box technique. The CTV included the whole uterus, vagina, parametrial region, as well as the regional lymph node (LN) area, and for PALN-positive patients, the PALN area was also irradiated. The planning target volume (PTV) consisted of the CTV plus a 0.5–1.0 cm margin. The daily dose was 1.8 to 2.0 Gy, delivered once a day, 5 days a week. Depending on tumor size, the whole pelvis was irradiated with up to 20 to 40 Gy, then a boost was performed, to between 50 to 50.4 Gy, to the parametrium with a 4 cm-wide central block using the antero-posterior parallel two-field technique. For PLN metastasis greater than or equal to 10 mm minimum in diameter on CT or MRI, a boost of 10 Gy in 2 Gy fractions was delivered to PLN metastases at the clinician’s discretion.

At the insertion of the central block to EBRT, HDR-ICBT was started, using an Iridium-192 remote afterloading technique, in 6 Gy fractions, once or twice a week, for a minimum of 3–4 fractions (microSelectron; Nucletron BV, Veenendaal, The Netherlands). In most cases, the combination of a tandem and Henschke-type ovoid applicator was used for the prescription at point A with CT-based image-guided volume optimization. In cases with lower vaginal extension, a tandem-cylinder was used for the prescription at the 2 cm-line from a tandem in the uterine cavity, and at a 5 mm-line from the applicator surface in the vagina, in order to fully cover the target. Implantation was performed under intravenous anesthesia. At the clinician’s discretion, patients with residual tumors received additional ICBT doses of 4.0–4.5 Gy per fraction. For patients with an anatomy not allowing for the application of standard ICBT wherein the tumor could not be encompassed, ISBT was selected. In such cases, EBRT was administered to the whole pelvis, without a central block, up to 45 Gy, and then ISBT was started. Implantation was performed under intravenous and epidural anesthesia through a transperineal route mainly using the Martinez Universal Perineal Interstitial Template (ELEKTA, Stockholm, Sweden). The irradiation was administered twice a day to the primary tumor, with at least 6 hours between each treatment session, for up to 24 Gy in 6 Gy fractions. Prior to 2013,
brachytherapy was planned based on CT using PLATO® (software v. 14.2.6, Nucletron). From 2013, Oncentra® Brachy Treatment Planning (ELEKTA) was used.

The doses to the tumor from both EBRT and HDR-ICBT (or HDR-ISBT) were normalized to the biologically equivalent doses in 2 Gy fractions (GyEQD2) based on the linear-quadratic model using an α/β ratio of 10 Gy.

Combined chemotherapy was used for patients with locally advanced disease (IIB–IVA), a bulky tumor larger than 4 cm as the minimum diameter, and/or LN metastasis. A chemotherapy agent was administered on the first day of RT. From 2001 to 2007, cisplatin was administered at 75 mg/m², tri-weekly, for 3 cycles. After 2007, cisplatin (40 mg/m², weekly, for 6 cycles) or nedaplatin (75–100 mg/m², tri-weekly, for 3 cycles) became the principal drugs of the chemotherapy regimen. At the clinician’s discretion, cases with advanced age, lower performance status, or renal dysfunction were given a reduction in dose.

**Follow-up and analysis of response and survival**

Follow-up was performed every month for the first year, every 2–3 months for the second year, and every 3–6 months thereafter. Follow-up procedures included physical and pelvic examinations, cervical Papanicolaou smears, and tumor markers. Chest to pelvic CT was scanned at an interval of 3–6 months for the first two years, and 6–12 months thereafter. Pelvic MRI or FDG-PET was performed when necessary.

A complete response (CR) was defined as no evidence of disease three months after the end of RT, evaluated by clinical and radiographic examinations. If there was persistence or progression of disease at that time, the effect of treatment was determined as “non-CR”. Disease after achieving of CR was defined as recurrence. A diagnosis of residual disease, progression, or recurrence was based on physical or radiographic examinations or pathological confirmation.
Statistical analyses were performed using JMP® 11 (SAS Institute Inc., Cary, NC, USA). The survival period was defined as the time between the start of RT and either progression, death from any cause, or the last follow-up date. Survival curves were calculated using the Kaplan-Meier method, and log-rank tests were used to compare survival distributions. Differences in patient or tumor characteristics were analyzed by the chi-square test or Fisher’s exact test for 2 x 2 columns. Differences with values of $P < 0.05$ were considered statistically significant.
Results

Patient characteristics

One hundred and thirty-seven reviewable patients formed the cervical cancer patient cohort for this analysis. The last follow-up was performed on September 2014. The crude median follow-up period for all patients and for surviving patients was 41.3 (range, 4.0–150.1) and 57.0 (range, 5.2–150.1) months, respectively. Patient and tumor characteristics are shown in Table 1. Briefly, the median age of all patients was 58 (range, 28–89) years, the most frequent stage was IIIB \( n=55 \) (40\%), and the median maximum tumor diameter measured by a T2-weighted image from MRI was 4.8 (range, undetectable–14.3) cm. Usually, HDR-ICBT using a tandem and Henschke-type ovoid applicator was performed; however, a tandem-cylinder applicator was used in 13 patients, and HDR-ISBT was performed in three patients. For 12 out of 15 patients treated during or before 2002, CT scans for HDR-ICBT was not obtained. Out of 48 PLN-positive patients, 12 patients received EBRT boosts.

Survival outcome

At the time of analysis, 92 patients were alive, and 45 patients had died–40 as a result of their malignancy and five due to other causes. The 5-year overall survival (OS) rate for all patients was 63.9 (± 4.6) %, and those for patients with stages I, II, III, and IVA disease were 87.1 (± 7.1) %, 78.0 (± 8.0) %, 54.3 (± 7.0) %, and 40.0 (± 12.7) %, respectively (Figure 1). The 5-year progression-free survival (PFS) rate for all patients was 60.6 (± 4.3) %.

Patterns of recurrence

The initial response and the patterns of recurrence are shown in Figure 2. Out of the 137 patients, 121 (88\%) patients achieved a CR. On the other hand, 16 (12\%) patients experienced persistence and/or progression of disease.
Among the 16 non-CR patients, all but one patient died of disease, with a median survival time (MST) of 10.9 (95% confidence interval (CI), 7.8–13.5) months from the start of RT. The remaining patient also died two months after the time of analysis.

Among the 121 patients with a CR, 36 (30%) patients developed recurrence, with a median interval of 9.3 (95% CI, 7.9–11.5) months from the start of RT. This interval was within one year in 69% of patients, and more than two years in only three (8.3%) patients. The MST from the recurrence was 16.4 (95% CI, 11.2–24.2) months. The first sites of recurrence were as follows: intra-RT field in nine, outside RT field in 20, and both intra- and outside RT field in seven patients.

Details of recurrence sites

The details of the non-CR patients and the first recurrence sites of recurrence patients are shown in Table 2, Table 3, Table 4, and Table 5.

Among 16 non-CR patients (Table 2), eight patients showed residual disease, of which three had synchronous distant progression, even though they received concurrent chemotherapy. The remaining eight patients experienced new distant metastasis without residual disease, even though all but one patient also received concurrent chemotherapy. Of these, new isolated PALN metastasis occurred in two patients. In this non-CR group, all patients showed locally advanced disease stages IIB–IVA, and there was a trend of younger patients, with a median age of 54 years. Clinicopathologic factors were compared between CR and non-CR patients by the chi-square test. As a result, non-CR patients significantly correlated with an advanced stage (III–IV vs. I–II, \( P = 0.0422 \)), a positive PLN (positive vs. negative, \( P = 0.0115 \)), a positive PALN (positive vs. negative, \( P = 0.0225 \)), a larger maximum tumor diameter (> 5cm vs. \( \leq 5 \) cm, \( P = 0.0001 \)), and a lower initial hemoglobin level (\( \leq 10 \) g/dL vs. > 10 g/dL, \( P = 0.0003 \)). All patients died of disease.

Next, within the intra-RT field recurrence group (Table 3), all patients had locally advanced disease. Although the tumor RT dose was not significantly lower (median tumor dose: 69.2 GyEQD\(_2\)
in patients with intra-field recurrence and 62.1 GyEQD$_2$ in patients without recurrence), all patients developed a local recurrence but interestingly, no one showed an isolated PLN recurrence. PALN failure after PALN irradiation was not observed. In this group, two patients with local recurrence alone were salvaged by surgery and survived for a long time.

In 20 patients with an outside RT field recurrence (Table 4), the lung was the most frequent site, observed in 12 (60%) patients. Oligo-recurrence of PALN occurred in only two initially PALN-negative patients. In this group, four patients were salvaged with no evidence of disease at the time of analysis; three with oligo-recurrence of lung were salvaged by surgery or stereotactic RT, and one with oligo-recurrence of mediastinal LN was salvaged by CRT; their survival periods from the time of recurrence were 48.0, 66.9, 36.1, 74.5 months, respectively. Furthermore, in this group, only four patients experienced afterwards a sequential intra-RT field recurrence, all within the next year. This means that the remaining patients suffered from a distant lesion alone.

In seven patients with both intra- and outside RT field recurrence (Table 5), five patients died of the original disease. The remaining two patients, both in the early period of their salvage chemotherapy, were still alive with disease.

In regards to the regional control of all 137 patients, 48 were PLN-positive and 89 were PLN-negative. Of the 48 PLN-positive patients, only 12 received EBRT boosts to the PLN metastasis and 36 did not (the median dose was 49.6 GyEQD$_2$ to the positive PLN, as well as regional areas). Two out of the 12 boosted patients, and four out of the 36 non-boosted patients, developed PLN persistence or recurrence as the first relapse, respectively. Of the 89 PLN-negative patients, one developed PLN recurrence as the first relapse. Thus, only seven (5.1%) patients developed PLN disease, and importantly, all of them were not isolated but showed another synchronous disease. Sites of nodal disease were the common iliac, internal iliac, and obturator LN, mainly (5/7 patients) at initially involved, not new, PLN. No disease was observed at the external iliac or presacral nodes.

PALN progression or recurrence was mostly new to initially PALN-negative patients; failure for initially involved PALN occurred in only one patient, and also with new and synchronous PALN
metastasis. Among PALN-negative patients (n=119), isolated PALN metastasis occurred in two patients up to three months after RT, and in two patients after achieving a CR [total, n=4 (4/119=3.4%)].

Discussion

Several reports concerning patterns of recurrence in cervical cancer have previously been published [6, 8-11]. Mazeron et al. reported that among 163 patients treated with CRT, those who developed distant metastasis as the first relapse amounted to 68.7% of all relapses, and, of these, half were isolated [6]. Teh et al. also reported that distant failures predominated over local failures, with local control rates of 81.7%, whereas distant control rates were 70.8% at 5 years [8]. Our results were also consistent with these reports. Outside RT field recurrence predominated over intra-RT field recurrence (20 vs. 9 patients among 36 recurrence patients). However, to our knowledge, this is the first report describing more detailed recurrence sites after definitive RT using modern treatment techniques, with additional findings from this detailed analysis.

Firstly, local persistence and recurrence accounted for half of non-CR patients and all of intra-RT field recurrence patients, respectively. This suggests the need for dose escalation to the primary tumor, especially in patients with locally advanced disease and/or patients who responded poorly to prior EBRT.

Indeed, the cumulative doses prescribed at point A adopted in Japan (62–65 GyEQD2) were remarkably lower than those used in global schedules (85 GyEQD2) [12]. In Japan, a phase II trial of concurrent CRT based on this schedule (JGOG 1066) was conducted, and demonstrated that it could provide favorable pelvic control and PFS rates; it appeared to be comparable to previously reported data, with a low incidence of severe late toxicity [12]. However, in this study, the authors also noted that there remained room for improvement in local control, particularly for patients with large tumors who frequently developed pelvic recurrence.

Furthermore, recent RT technology in brachytherapy is becoming highly precise, especially in IGBT. Planning aims have also changed to deliver to 90% of High Risk CTV (D90), not to point A,
following the recommendation of the Groupe Européen de Curiethérapie-European SocieTy for Radiotherapy & Oncology (GEC-ESTRO) [13]. Dimopoulos et al. demonstrated a dose-effect relationship in patients treated with HDR-MRI-guided brachytherapy [14]. Pötter et al. showed excellent local control rates, even in advanced disease, using MRI-guided adaptive ICBT including needle insertion (prescribed to D90 > 85 Gy) [7]. As a result, presently in our institution, MRI-guided ICBT is administered particularly to advanced cases, and we also prescribe at least 6 Gy per fraction to D90.

Secondly, regional control was favorable, even in initially PLN-positive patients. Of all 137 patients, including 48 PLN-positive patients, only seven (5.1%) patients developed PLN disease, and importantly, all of them were not isolated but displayed another synchronous disease. Recently, several researchers have reported the efficacy of EBRT boosts to metastatic PLN to reduce PLN recurrence [15-20]. However, this current analysis suggests that EBRT boosts may not be necessary for all PLN-positive cases, because nodal control was favorable and PLN persistence and recurrence were always observed with other synchronous relapses. PLN metastasis is reported to be a significant prognostic indicator for developing distant metastasis, including PALN recurrence [15, 20]. Therefore, additional systemic chemotherapy, with or without prophylactic PALN irradiation, rather than EBRT boosts may be an appropriate treatment option to further improve outcomes for patients with positive PLN.

Additionally in regards to regional areas, sites of nodal disease were the common iliac, internal iliac, and obturator LN, while disease was not observed at the external iliac nor presacral nodes. Kasuya et al. investigated details of distribution patterns of metastatic PLNs in patients with cervical cancer [21]. There were some differences of definition of regional areas between this study and our study, and in this study, regional areas were further divided into some sub-regions. The majority of patients had positive nodes in the cranial obturator and/or the medial external iliac region. In contrast, few had positive nodes in the lateral external iliac, caudal external iliac, caudal obturator, internal iliac and presacral regions. All these areas have usually been included in standard CTV. However, using
intensity-modulated radiation therapy (IMRT), a dose adjustment in these regional areas, divided into high and low risk areas, will become possible in PLN-negative patients.

Isolated PALN metastasis was less frequent than was first thought, occurring in two patients up to three months after RT, and in two patients after achieving CR, among 119 PALN-negative patients (4/119=3.4%). Cervical cancer spreads through the lymphatic route rather than hematogenously [22, 23] and the first site of distant metastasis is PALN. This has been confirmed in a large population-based study [22, 23]. Furthermore, RT for oligo-recurrence of PALN has been well reported [24]. However, the benefits of extended field RT plus chemotherapy in PLN-positive patients with a supposedly 20–25% risk of subclinical PALN involvement remain unclear. Our findings suggest that such benefits may be limited. Yap et al. also reported, in their prospective study of 228 patients treated with CRT, that the addition of PALN irradiation was not associated with a significant difference in disease-free survival, OS, and the rate of PALN relapse [25]. In their study, isolated PALN relapse rates after pelvic RT alone were 2.6%. They theorized that cisplatin chemotherapy effectively treated micro-metastatic disease in the para-aortic chain and offset the potential benefit of PALN irradiation. Furthermore, our findings suggest that the most frequent isolated distant metastatic site in cervical cancer has changed from PALN to lung in the era of CRT.

The predominance of outside RT field recurrence over intra-RT field recurrence, and that almost all patients with outside RT field recurrence alone were free from intra-RT field recurrence for a long time, both highlight the issue of distant control. Reducing distant failures is a challenge that must be faced in order to improve outcomes. Recently, the need for consolidation chemotherapy for selected patients with locally advanced cervical cancer has been under debate [26]. We think that patients who achieve a benefit from adjuvant chemotherapy will be present in definite proportions. The Gynecologic Oncology Group is also starting a randomized study on adjuvant chemotherapy in high-risk patients (three cycles of carboplatin plus paclitaxel), termed the OUTBACK Trial [27]. In addition, several molecular targeting agents are being used for cancer patients [16].
Finally, isolated recurrences may have a chance to be cured with aggressive local cancer treatments such as RT or surgery, with or without chemotherapy. In this current study, two cases with isolated local recurrences were salvaged by surgery, and three cases in the oligo-recurrent state also gained in longer survival times after salvage surgery or RT. Oligo-recurrence has been defined by Niibe and it is one of the recent topics in oncology [23, 28, 29]. In the state of oligo-recurrence, recurrent sites with a controlled primary lesion were treated with local therapy, meaning that all gross recurrent sites could be treated using local therapy [23]. Careful follow-up plus being alert to an opportunity for salvage therapy were important.

There was a potential limitation in this study in that due to the nature of it being a retrospective study, there was a lack of consistency in patients, diseases, treatments, and in assessments of toxicity.

In conclusion, local disease was a major type of intra-RT field recurrence. This suggests that there remains room for improvement in local control. On the other hand, PLN control was favorable, even in initially PLN-positive patients, and PLN may be able to be divided into high and low risk areas. Furthermore, the predominance of outside RT field recurrence alone highlights issues of distant control, including the intensity enhancement of systematic therapy.
Figure legends

**Figure 1.** Survival curves showing FIGO stage-based overall survival rates.

**Figure 2.** The initial response and patterns of first recurrence. Abbreviations: CR = complete response, Rec = recurrence, RT = radiation therapy, DOD = died of disease, AWD = alive with disease, NED = no evidence of disease, MST = median survival time, mo = months
References

1. NCI Press Office. NCI Issues Clinical Announcement on Cervical Cancer: Chemotherapy plus Radiation Improves Survival. Bethesda, MD: National Institutes of Health (NIH); Available at URL: http://www.nih.gov/news/pr/feb99/nci-22.htm. Accessed on April 10, 2015.

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Cervical Cancer Version 2. 2015. Fort Washington, PA: National Comprehensive Cancer Network; Available at URL: http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed on April 10, 2015.

3. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002 Jan;38(2):270-8.

4. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010;20:CD008285. Available at URL: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008285/full. doi: 10.1002/14651858.CD008285.

5. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 26:5802-12.

6. Mazeron R, Gilmore J, Dumas I, Champoudry J, Goulart J, Vanneste B, Tailleur A, Morice P, Haie-Meder C. Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist. 2013;18(4):415-22.

7. Pötter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, Georg D, Schmid MP, Reinthaller A, Sturdza A, Kirisits C. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011 Jul;100(1):116-23.
8. Teh J, Yap SP, Tham I, Sethi VK, Chua EJ, Yeo R, Ho TH, Tay EH, Chia YN, Soh LT, Khoo-Tan HS. Concurrent chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors. Int J Gynecol Cancer. 2010 Apr;20(3):428-33.

9. Mazeron R, Castelnau-Marchand P, Dumas I, Del Campo ER, Kom LK, Martinetti F, Farha G, Taillleur A, Morice P, Chargari C, Lefkopoulos D, Haie-Meder C. Impact of treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemoradiation and image-guided pulsed-dose rate adaptive brachytherapy. Radiother Oncol. 2014 Dec 10. pii: S0167-8140(14)00560-X.

10. Parker K, Gallop-Evans E, Hanna L, Adams M. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):140-6.

11. Chen SW, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, Yang SN, Lin FJ. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1370-7.

12. Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG). Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol. 2012 Aug;126(2):211-6.

13. Haie-Meder C, Pöttcr R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, Dumas I, Hellebust TP, Kirisits C, Lang S, Muschitz S, Nevinson J, Nulens A, Petrow P, Wachter-Gerstner N; Gynaecological (GYN) GEC-ESTRO Working Group. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based
3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005 Mar;74(3):235-45.

14. Dimopoulos JC, Pötter R, Lang S, Fidarova E, Georg P, Dörr W, Kirisits C. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol. 2009 Nov;93(2):311-5.

15. Ariga T, Toita T, Kasuya G, Nagai Y, Inamine M, Kudaka W, Kakinohana Y, Aoki Y, Murayama S. External beam boost irradiation for clinically positive pelvic nodes in patients with uterine cervical cancer. J Radiat Res. 2013 Jul 1;54(4):690-6.

16. Wakatsuki M, Ohno T, Kato S, Ando K, Noda SE, Kiyohara H, Shibuya K, Karasawa K, Kamada T, Nakano T. Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer. J Radiat Res. 2014 Jan 1;55(1):139-45.

17. Hata M, Koike I, Miyagi E, Numazaki R, Asai-Sato M, Kasuya T, Kaizu H, Matsui T, Hirahara F, Inoue T. Radiation therapy for pelvic lymph node metastasis from uterine cervical cancer. Gynecol Oncol. 2013 Oct;131(1):99-102.

18. Rash DL, Lee YC, Kashefi A, Durbin-Johnson B, Mathai M, Valicenti R, Mayadev JS. Clinical response of pelvic and para-aortic lymphadenopathy to a radiation boost in the definitive management of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):317-22.

19. Vargo JA, Kim H, Choi S, Sukumvanich P, Olawaiye AB, Kelley JL, Edwards RP, Comerci JT, Beriwal S. Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1091-8.

20. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):706-12.
21. Kasuya G, Toita T, Furutani K, Kodaira T, Ohno T, Kaneyasu Y, Yoshimura R, Uno T, Yogi A, Ishikura S, Hiraoka M. Distribution patterns of metastatic pelvic lymph nodes assessed by CT/MRI in patients with uterine cervical cancer. Radiat Oncol. 2013 Jun 8;8:139.

22. Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Li N, Suzuki K, Uno T, Tokumaru S, Takayama M, Sekiguchi K, Matsumoto Y, Michimoto K, Oguchi M, Hayakawa K. Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol. 2006 Nov;103(2):435-8.

23. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010 Feb;40(2):107-11.

24. Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, Kataoka M, Suzuki K, Li N, Uno T, Takanaka T, Higuchi K, Yamazaki H, Tokumaru S, Oguchi M, Hayakawa K; Japanese Isolated Para-Aortic Lymph Node Recurrence of Uterine Cervical Carcinoma Study Group. Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1366-9.

25. Yap ML, Cuartero J, Yan J, Pintilie M, Fyles A, Levin W, Manchul L, Milosevic M. The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer. Clin Oncol (R Coll Radiol). 2014 Dec;26(12):797-803.

26. Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya S, Supawattanabodee B. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database Syst Rev. 2014 Dec 3;12:CD010401.

27. ClinicalTrials.gov. Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer. Bethesda, MD: National Library of Medicine (NLM) at National Institutes of Health (NIH); Available at https://clinicaltrials.gov/ct2/show/NCT01414608. Accessed March 26, 2015.
28. Niibe Y1, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012;2012:261096.

29. Iwata S, Yonemoto T, Iizasa T, Niibe Y, Kamoda H, Ishii T. Oligo-Recurrence of Osteosarcoma Patients: Treatment Strategies for Pulmonary Metastases. Ann Surg Oncol. 2015 Jun 20.
Conflict of Interest Statement

The authors declare no conflicts of interest.
**Table 1.** Patient and tumor characteristics.

| Characteristic                          | Number | %    |
|----------------------------------------|--------|------|
| Number of patients                     | 137    |      |
| Age (years)                            | median: 58 (range: 28–89) |
| Histology                              |        |      |
| Squamous cell carcinoma                | 115    | 84%  |
| Non-squamous cell carcinoma            | 22     | 16%  |
| FIGO stage                             |        |      |
| IB1                                     | 21     | 15%  |
| IB2                                     | 7      | 5%   |
| IIA1                                    | 9      | 7%   |
| IIA2                                    | 1      | 1%   |
| IIB                                     | 20     | 15%  |
| IIIA                                    | 9      | 7%   |
| IIIB                                    | 55     | 40%  |
| IVA                                     | 15     | 11%  |
| Pelvic lymph node metastasis           |        |      |
| Positive                               | 48     | 35%  |
| Negative                               | 89     | 65%  |
| Size of positive pelvic lymph node (cm) | median: 1.2 (range: 0.6–3.6) |
| Para-aortic lymph node metastasis      |        |      |
| Positive                               | 18     | 13%  |
| Negative                               | 119    | 87%  |
| Initial hemoglobin (g/dL)              | median: 12.1 (range: 4.4–15.1) |
| Maximum tumor diameter (cm)            | median: 4.8 (range: 0–14.3) |
| Concurrent chemotherapy                |        |      |
| With                                   | 112    | 82%  |
| Tri-weekly CDDP 75 mg/m²               | 36     | 26%  |
| Tri-weekly NDP 80 mg/m²                | 53     | 39%  |
| Weekly CDDP 40 mg/m²                   | 20     | 15%  |
| Others                                 | 3      | 2%   |
| Without                                | 25     | 18%  |
| RT duration (days)                     | median: 46 (range: 35–89) |
| RT dose (GyEQD2)                       |        |      |
| point A or primary tumor               | median: 63.9 (range: 40–91.1) |
| peripheral region                      | median: 49.6 (range: 40–50)  |
| metastatic lymph node                  | median: 49.6 (range: 44.3–60) |

FIGO, the International Federation of Gynecology and Obstetrics; CDDP, cisplatin; NDP, nedaplatin; RT, radiation therapy.
Table 2. Details of non-CR patients (n=16).

| Age (y) | Histology | FIGO stage | PLN | PALN | First progression sites |
|---------|-----------|------------|-----|------|-------------------------|
| 56      | SqCC      | IIIB       |     |      | Local                   |
| 39      | SqCC      | IIIB      + |     |      | Regional                |
| 69      | SqCC      | IIIB      + |     |      | PALN (N)                |
| 63      | SqCC      | IIIB       |     |      | Bone                   |
| 53      | SqCC      | IVA       + + |     |      | Adrenal gland          |
| 38      | SqCC      | IIIB       |     |      | PALN (N)                |
| 76      | AC        | IIB        + |     |      | Local                   |
| 51      | SqCC      | IIIB      + + |     |      | Local                   |
| 71      | AC        | IIB        + |     |      | Local                   |
| 57      | SqCC      | IVA       + + |     |      | Lung                   |
| 28      | SqCC      | IIB      + + |     |      | Local                   |
| 44      | SqCC      | IIB        + |     |      | Local                   |
| 81      | SqCC      | IVA        + |     |      | Local                   |
| 40      | SqCC      | IVA      + + |     |      | Local                   |
| 55      | SqCC      | IVA        |     |      | Bone                   |
| 45      | SqCC      | IIIB       + |     |      | Lung                   |

CR, complete response; FIGO, the International Federation of Gynecology and Obstetrics; PLN, pelvic lymph node; PALN, para-aortic lymph node; SqCC, squamous cell carcinoma; AC, adenocarcinoma; I, involved initially; N, new; LN, lymph node.
Table 3. Details of first recurrence sites of intra-RT field recurrence patients (n=9).

| Age (y) | Histology | FIGO stage | PLN | PALN | First recurrence sites |
|---------|-----------|------------|-----|------|------------------------|
| 67      | SqCC      | IIIB       |     |      | Local                  |
| 65      | AC        | IIIB       |     |      | Local                  |
| 66      | SqCC      | IIIB       | +   |      | Local                  |
| 72      | SqCC      | IVA        | +   |      | Local                  |
| 72      | SqCC      | IVA        |     |      | Local                  |
| 79      | SqCC      | IIIB       |     |      | Local obturator (N)    |
| 72      | SqCC      | IIIB       |     |      | Local                  |
| 62      | SqCC      | IIIB       | +   |      | Local                  |
| 44      | SqCC      | IVA        |     |      | Local                  |

RT, radiation therapy; FIGO, the International Federation of Gynecology and Obstetrics; PLN, pelvic lymph node; PALN, para-aortic lymph node; SqCC, squamous cell carcinoma; AC, adenocarcinoma; N, new.
Table 4. Details of outside RT field recurrence patients (n=20).

| Age (y) | Histology | FIGO stage | PLN | PALN         | First recurrence sites |
|---------|-----------|------------|-----|--------------|------------------------|
| 61      | SqCC      | IIIB       |     |              | PALN                   |
| 51      | SqCC      | IIIB       |     | PALN (N)     | Lung                   |
| 44      | SqCC      | IIIB       | +   | +            | LN                     |
| 48      | SqCC      | IIIB       | +   |              | Lung                   |
| 72      | SqCC      | IB1        |     |              | Lung                   |
| 57      | SqCC      | IIIB       |     | PALN (N)     |                        |
| 65      | SqCC      | IVA        | +   | +            | Spleen, peritoneum     |
| 61      | SqCC      | IIIB       | +   | +            | LN                     |
| 77      | AC+SqCC   | IIIB       |     | PALN (N)     |                        |
| 59      | SqCC      | IIB        |     |              | Lung                   |
| 58      | SqCC      | IIA        | +   |              | Lung                   |
| 62      | SqCC      | IIB        |     | PALN (N)     | Liver, LN              |
| 77      | SqCC      | IIB        | +   | +            | Lung                   |
| 44      | SqCC      | IIB        |     |              | Lung                   |
| 64      | SqCC      | IIIB       | +   | +            | LN                     |
| 33      | SqCC      | IB2        |     |              | Lung                   |
| 70      | SqCC      | IVA        |     |              | LN                     |
| 63      | AC+SqCC   | IIA        |     | PALN (N)     | Lung                   |
| 38      | SqCC      | IB2        |     |              | Lung                   |
| 89      | AC        | IIIB       |     |              | Lung                   |

RT, radiation therapy; FIGO, the International Federation of Gynecology and Obstetrics; PLN, pelvic lymph node; PALN, para-aortic lymph node; SqCC, squamous cell carcinoma; AC, adenocarcinoma; N, new; LN, lymph node.
Table 5. Details of both of intra- and outside RT field recurrence patients (n=7).

| Age (y) | Histology | FIGO stage | PLN | PALN | First recurrence sites |
|---------|-----------|------------|-----|------|------------------------|
| 47      | SqCC      | IIIB       | +   | Local | common iliac (I)       |
|         |           |            |     |       | internal iliac (I)     |
|         |           |            |     |       | obturator (I)          |
|         |           |            |     |       | PALN (N)               |
| 53      | SqCC      | IIIB       | +   | Local | common iliac (I)       |
|         |           |            |     |       | internal iliac (I)     |
|         |           |            |     |       | obturator (I)          |
|         |           |            |     |       | PALN (N)               |
| 50      | SqCC      | IIIB       | +   | +     | Local                  |
|         |           |            |     |       | PALN (N)               |
| 64      | AC        | IB2        | +   | Local | common iliac (I)       |
|         |           |            |     |       | PALN (N)               |
| 42      | AC        | IIIB       | +   | +     | common iliac (I)       |
|         |           |            |     |       | Lung peritoneum        |
| 73      | SqCC      | IIIB       | +   | +     | PALN (I, N)            |
| 68      | SqCC      | IIIB       | +   | obturator (N)          |
|         |           |            |     |       | PALN (N)               |

RT, radiation therapy; FIGO, the International Federation of Gynecology and Obstetrics; PLN, pelvic lymph node; PALN, para-aortic lymph node; SqCC, squamous cell carcinoma; AC, adenocarcinoma; I, involved initially; N, new; LN, lymph node.
Total 137

Non-CR
16 (12%)

CR
121 (88%)

MST from start of RT: 10.7 mo

Rec-
85 (70%)

Intra-RT field
9

DOD 7
AWD 1
NED 2

Rec+
36 (30%)

Both
7

DOD 5
AWD 2
NED 4

Median interval from start of RT: 9.3 mo
MST from Rec: 16.4 mo
MST from start of RT: 24.4 mo

Outside RT field
20

DOD 13
AWD 3
NED 4

Survival period from Rec: 74.5, 48.0, 66.9, 36.1 mo
Overall survival rates

Stage IB
Stage II
Stage III
Stage IVA

$P = 0.0017$